Incysus Therapeutics Announces Name Change to IN8bio, Inc.
August 24, 2020 07:00 ET
|
IN8bio, Inc.
NEW YORK, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on delivering innovative gamma-delta (γδ) T cell immunotherapies for the...
Incysus Therapeutics Treats First Patient in Phase 1 Study of Gamma Delta (γδ) T Cell Immunotherapy in Leukemia and Lymphoma Patients Undergoing Allogeneic Stem Cell Transplantation
May 12, 2020 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Lawrence Lamb, Ph.D., Incysus Therapeutics Scientific Co-Founder to Present at Allogenic Cell Therapies Summit 2019 (ACTS)
May 02, 2019 08:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, May 02, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...